DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS  
BOARD OF PHARMACY  
PHARMACY CONTROLLED SUBSTANCES  
(By authority conferred on the board of pharmacy by sections 7201, 7219, 7301, and  
16204e of 1978 PA 368, MCL 333.7201, 333.7219, 333.7301, and 333.16204e and  
Executive Reorganization Order Nos. 1991-9, 1996-2, 2003-1, and 2011-4, MCL  
338.3501, 445.2001, 445.2011, and 445.2030)  
PART 1. GENERAL PROVISIONS  
R 338.3101 Definitions; A to H.  
Rule 1. As used in these rules:  
(a) "Act" means 1978 PA 368, MCL 333.1101 et seq.  
(b) "Deleterious drug" means a drug, other than a proprietary medicine, that is likely  
to be destructive to adult human life in quantities of 3.88 grams or less.  
(c) "Department" means the department of community health.  
(d) "Electronic signature" means an electronic sound, symbol, or process attached  
to or logically associated with a record and executed or adopted by a person with the  
intent to sign the record. An electronic signature also is a unique identifier  
protected by appropriate security measures such that it is only available for use by  
the intended individual and ensures nonrepudiation so that the signature may not  
be rejected based on its validity.  
History: 1979 AC; 1992 AACS; 2002 AACS; 2004 AACS.  
R 338.3102 Definitions; I to P.  
Rule 2. (1) As used in these rules:  
(a) "Inventory" means all stocks in finished form of a controlled substance that is  
manufactured or otherwise acquired by a licensee, whether in bulk or commercial  
containers or contained in pharmaceutical preparations in the possession of the  
licensee.  
(b) "Licensee" means a person who is licensed pursuant to section 7303 of the act.  
(c) "Michigan automated prescription system (maps) claim form" means a form, to  
be determined by the department, that is in the format and includes the information  
as specified by the american society for automation in pharmacy (asap) and contains the  
information specified in R 338.3162b.  
(d) "National drug code number (ndc)" means a number  
that  
identifies the  
labeler/vendor, product, and package size and is assigned to each drug product listed  
under section 510, registration of producers of drugs and devices, of the federal food,  
drug, and cosmetic act.  
Page 1  
(e) "Officer" means a state, county, or local law enforcement officer who has a duty  
to enforce the laws of this state.  
(f) "Patient identifier" includes all of the following information about a patient:  
(i) Full name.  
(ii) Address, including zip code.  
(iii) Date of birth.  
(iv) Any 1 of the following:  
(A) A Michigan driver's license number.  
(B) An identification number obtained from a photo identification card issued by  
the state of Michigan.  
(C) The number zero. Zeroes shall be entered as the identification number, if the  
positive identification presented by the patient or the patient's agent or caregiver does  
not include a license  
number  
or  
an identification number, as listed in  
subparagraphs (A) and (B) of this  
paragraph.  
(g) "Positive identification" means identification that includes a photograph of an  
individual in addition to his or her date of birth. Positive identification shall include  
an identification card issued by a governmental agency, provided the identification  
card meets the requirements of this rule.  
(2) As used in part 5 of these rules:  
(a) "Medical institution" means an inpatient health facility which is licensed or  
approved by the state and which directly or indirectly provides or includes pharmacy  
services.  
(b) "Pharmacy services" means the direct and indirect patient care services  
associated with the practice of pharmacy.  
History: 1979 AC; 1980 AACS; 1992 AACS; 2002 AACS; 2003 AACS; 2004 AACS; 2007 AACS.  
R 338.3104 Definitions; R, S.  
Rule 4. As used in these rules:  
(a) "Readily retrievable" means a record which is kept in such a manner that it can be  
separated from all other records within 48 hours and in which a listed controlled  
substance shall be marked with an asterisk, redlined, or in some other manner be  
visually identifiable apart from the other substances listed in the record.  
(b) "Scientific investigator" means a person, other than a physician, who is licensed to  
conduct research with a controlled substance listed in schedules 1 to 5.  
(c) "Sign" means to affix a signature manually in the same manner as signing a  
check or legal document or to use an electronic signature, as defined in subdivision  
(d) of R 338. 3101. Stamped signatures are not valid for any controlled substance  
prescription.  
(d) "Substance" means a controlled substance unless  
otherwise.  
the  
context indicates  
History: 1979 AC; 1992 AACS; 2003 AACS.  
Page 2  
R 338.3108 Terms defined in act.  
Rule 8. Terms defined in the act have the same meanings when used in these rules.  
History: 1992 AACS.  
R 338.3109 Rescission.  
Rule 9. Rules 14, 21, and 22 of the board, being R 338.484, R 338.491 and R  
338.492 of the Michigan Administrative Code and appearing on pages 2880 and 2885  
of the 1963 Annual Supplement of the Code, are rescinded.  
History: 1979 AC.  
PART 2. SCHEDULES  
R 338.3111 Schedule 1; opiates.  
Rule 11. Unless specifically excepted, the following opiates including their isomers,  
esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of such  
isomers, esters, ethers, and  
salts  
is possible within the specific chemical  
designation, are included in schedule 1:  
(a) Acetyl-alpha-methylfentanyl.  
(b) Acetylmethadol.  
(c) Allylprodine.  
(d) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-  
acetylmethadol, levomethadyl acetate, or LAAM.  
(e) Alphameprodine.  
(f) Alphamethadol.  
(g) Alpha-methylfentanyl.  
(h) Alpha-methylthiofentanyl.  
(i) Benzethidine.  
(j) Betacetylmethadol.  
(k) Beta-hydroxyfentanyl.  
(l) Beta-hydroxy-3-methylfentanyl.  
(m) Betameprodine.  
(n) Betamethadol.  
(o) Betaprodine.  
(p) Clonitazene.  
(q) Dextromoramide.  
(r) Diampromide.  
(s) Diethylthiambutene.  
(t) Difenoxin.  
(u) Dimenoxadol.  
(v) Dimepheptanol.  
(w) Dimethylthiambutene.  
(x) Dioxaphetyl butyrate.  
Page 3  
(y) Dipipanone.  
(z) Ethylmethylthiambutene.  
(aa) Etonitazene.  
(bb) Etoxeridine.  
(cc) Furethidine.  
(dd) Hydroxypethidine.  
(ee) Ketobemidone.  
(ff) Levomoramide.  
(gg) Levophenacylmorphan.  
(hh) MPPP(1-methyl-4-phenyl-4-propionoxypiperidine).  
(ii)3-methylfentanyl(n-(3-methyl-1-2-phenylethyl)-4- piperidyl)-n-phenylpropanamide).  
(jj) 3-Methylthiofentanyl.  
(kk) Morpheridine.  
(ll) Noracymethadol.  
(mm) Norlevorphanol.  
(nn) Normethadone.  
(oo) Noripipanone.  
(pp) Para-fluorofentanyl.  
(qq) PEPAP(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine.  
(rr) Phenadoxone.  
(ss) Phenampromide.  
(tt) Phenomorphan.  
(uu) Phenoperidine.  
(vv) Piritramide.  
(ww) Proheptazine.  
(xx) Properidine.  
(yy) Propiram.  
(zz) Racemoramide.  
(aaa) Thiofentanyl.  
(bbb) Tilidine.  
(ccc) Trimeperidine.  
History: 1979 AC; 1982 AACS; 1985 AACS; 1986 AACS; 1988 AACS; 1995 AACS.  
R 338.3112 Schedule 1; opium derivatives.  
Rule 12. Unless specifically excepted, the following opium derivatives, their salts,  
isomers and salts of isomers, when the existence of these salts, isomers and salts of  
isomers is possible within the specific chemical designation, are included in schedule 1:  
Substance  
a
b
c
d
e
Acetorphine  
Acetyldihydrocodeine  
Benzylmorphine  
Codeine methylbromide  
Codeine-N-Oxide  
Page 4  
f
Cyprenorphine  
g
h
i
Desomorphine  
Dihydromorphine  
Drotebanol  
j
k
l
m
n
o
p
q
r
Etorphine (except hydrochloride salts)  
Heroin  
Hydromorphinol  
Methyldesorphine  
Methyldihydromorphine  
Morphine methylbromide  
Morphine methylsulfonate  
Morphine-N-Oxide  
Myrophine  
s
Nicocodeine  
t
Nicomorphine  
u
v
w
Normorphine  
Pholcodine  
Thebacon  
History: 1979 AC; 2013 AACS.  
R 338.3113 Schedule 1; hallucinogenic substances.  
Rule 13. Unless specifically excepted, any material, compound, mixture, or  
preparation that is not otherwise listed as a controlled substance in this schedule or in  
schedules II through V, is not approved by the federal food and drug administration as a  
drug, and contains any quantity of the following hallucinogenic substances, their salts,  
isomers (whether optical, positional, or geometric), homologues (analogs), and salts of  
isomers and homologues (analogs), whenever the existence of these salts, isomers,  
homologues (analogs) and salts of isomers and homologues (analogs) is possible within  
the specific chemical designation, is included in schedule 1:  
Substance  
Trade or Other Names  
a
b
c
d
1-(1-(2-thienyl)cyclohexyl)pyrrolidine  
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine  
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine 2C-D  
TCPY  
2C-E  
2-(2,5-Dimethoxy-4-(n)-  
2C-P  
propylphenyl)ethanamine  
e
f
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine  
2-(2,5-Dimethoxyphenyl)ethanamine  
2C-N  
2C-H  
g
h
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine 2C-C  
2-(4-Ethylthio-2,5-  
2C-T-2  
dimethoxyphenyl)ethanamine  
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine  
2-[(4-Isopropylthio)-2,5-  
i
j
2C-I  
2C-T-4  
dimethoxyphenyl)]ethanamine  
Page 5  
k
l
2,5-dimethoxy-4-ethylamphetamine  
2,5-dimethoxy-4-(n)-propylthiophenethylamine 2C-T-7  
DOET  
m
2,5-dimethoxyamphetamine  
2,5-dimethoxy-alpha-  
methylphenethylamine  
2,5-DMA  
n
o
p
q
r
3,4-methylenedioxy-n-ethylamphetamine  
3,4-methylenedioxyamphetamine  
3,4-methylenedioxymethamphetamine  
3,4,5-trimethoxyamphetamine  
MDMA  
4-bromo-2,5-dimethoxphenethylamine  
2-(4-bromo-2-5-  
dimethoxyphenyl)-1-  
aminoethae  
desmethyl DOB  
2c-b  
nexus  
s
t
4-bromo-2,5-dimethoxyamphetamine  
4-methoxyamphetamine  
4-bromo-2,5 dimethoxy-  
alpha-methylphenethylamine  
4 bromo-2,5-DMA  
4-methoxy-alpha-  
methylphenethylamine  
Paramethoxyamphetamine  
PMA  
u
4-methyl-2,5-dimethoxyamphetamine  
4-methyl-2,5-dimethoxy-  
alpha-methylphenethylamine  
DOM  
STP  
v
w
x
5-methoxy-3,4-methylenedioxyamphetamine  
5-methoxy-N, N-diisopropyltryptamine  
5-methoxy-N, N-dimethyltryptamine  
Alpha-ethyltryptamine  
5-MeO-DiPT  
5-MeO-DMT  
etryptamine  
y
monase  
a-ethyl-1h-indole-3-  
ethanamine  
3-(2-aminobutyl)indole  
a-et  
AE  
z
Bufotenine  
3-(beta-dimethylaminoethyl)-  
5-hydroxyindole  
3-(2-dimethylaminoethyl)-5-  
indolol  
N,N-dimethyserotonin  
5-hydroxy-N-N-  
dimethyltryptamine  
mappine  
Page 6  
aa  
Diethyltryptamine  
N, N-Diethyltryptamine  
DET  
bb  
cc  
Dimethyltryptamine  
Ethylamine analog of phencyclidine  
DMT  
n-ethyl-1-  
phenylcyclohexylamine  
(1-  
phenylcyclohexyl)ethylamine  
n-(1-  
phenylcyclohexyl)ethylamine  
cyclohexamine  
PCE  
dd  
Ibogaine  
7-Ethyl-  
6,6beta,7,8,9,10,12,13-  
octahydro-2-methoxy-6, 9-  
methano-5H-pyrido  
[1’,2’:1.2]azepino[5,4-  
b]indole  
tabernanthe iboga  
ee  
ff  
Lysergic acid diethylamine  
Marihuana  
gg  
hh  
ii  
jj  
kk  
Mescaline  
N-ethyl-3-piperidyl benzilate  
N-hydroxy-3,4-methylenedioxyamphetamine  
N-methyl-3-piperidyl benzilate  
Parahexyl  
3-hexyl-1-hydroxy-7,8,9,10-  
tetrahydro-6,6,9-trimethyl-  
6Hdibenzol[b,d]pyran  
synhexyl  
ll  
Peyote  
mm Psilocybin  
nn  
oo  
Psilocyn  
Pyrrolidine analog of phencyclidine  
1-(1-phenylcyclohexyl)-  
pyrrolidine  
PCPy  
PHP  
pp  
qq  
Thiophene analog of phencyclidine  
1-[1-(2-thienyl)-cyclohexyl]-  
piperidine  
2-thienyl-analog of  
phencyclidine  
TPCP  
TCP  
Any derivative of phenethylamine with single  
or multiple alkyl, halogen, alkoxy, or  
substituted C,S,N, or O groups on the aromatic  
ring and/or fused variations, with or without  
Page 7  
alkyl substituents on the ethylamine moiety  
and/or single or multiple alkyl, halogen,  
hydroxyl, or alkoxy including methoxybenzyl  
substitution which shall include but not be  
limited to, all of the following:  
i
1-(2,5-dimethoxy-4-idophenyl)-propan-2-  
amine  
DOI  
2,5-Dimethoxy-4-  
iodoamphetamine  
DOB  
2,5-Dimethoxy-4-  
bromoamphetamine  
bromo-  
ii  
iii  
1-(4-Bromo-2,5-dimethoxyphenyl)-2-  
aminopropane  
1-(4-Bromofuro[2,3-f][1]benzofuran-8-  
yl)propan-2-amine  
benzodifuranylisopropylamin  
e
bromo-dragonFLY  
DOC  
2,5-Dimethoxy-4-  
chloroamphetamine  
2C-T  
4-methylthio-2,5-  
dimethoxyphenethylamine  
2C-N  
2,5-Dimethoxy-4-  
nitrophenethylamine  
2C-C-NBOMe  
25C-NBOMe  
2,5-Dimethoxy-4-chloro-N-  
(2-  
iv  
v
1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-  
amine  
2-(2,5-dimethoxy-  
4(methylthio)phenyl)ethanamine  
vi  
vii  
2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine  
2-(4-chloro-2,50dimethoxyphenyl)-N-[(2-  
methoxyphenyl)methyl]ethanamine  
methoxybenzyl)phenethylami  
ne  
viii  
2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-  
methoxyphenyl)methyl]ethanamine  
2C-I-NBOMe  
25I-NBOMe  
2,5-Dimethoxy-4-iodo-N-(2-  
methoxybenzyl)phenethylami  
ne  
ix  
x
2-(7-Bromo-5-methoxy-2,3-dihydro-1-  
benzofuran-4-yl)ethanamine  
2-(8-bromo-2,3,6,7-tetrahydrofuro[2,3-  
f][1]benzofuran-4-yl)ethanamine  
2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-  
g]chromen-5-yl)ethanamine  
2CB-5-hemiFLY  
2C-B-FLY  
xi  
xii  
5-(2-Aminopropyl)-2,3-dihydrobenzofuran  
5-(2-Aminopropyl)benzofuran  
5-(2-Aminopropyl)indole  
5-APDB  
5-APB  
5-IT  
xiii  
xiv  
xv  
5-methoxy-3,4-methylenedioxy-amphetamine  
Page 8  
xvi  
6-(2-Aminopropyl)-2,3-dihydrobenzofuran  
6-APDB  
xvii 6-(2-Aminopropyl)benzofuran  
xviii N-(2-Hydroxybenzyl)-4-iodo-2,5-  
dimethoxyphenethylamine  
6-APB  
2C-INBOH  
25I-NBOH  
2C-B-FLY-NBOME  
xix  
N-(2-Hydroxybenzyl-4-iodo-2,5-  
dimethoxyphenethylamine  
xx  
N-(2-Methoxybenzyl)-2-(3,4,5-  
trimethoxyphenyl)ethanamine  
Mescaline-NBOME  
3,4,5-trimethoxy-N-(2-  
methoxybenzyl)  
phenethylamine  
History: 1979 AC; 1986 AACS; 1988 AACS; 1994 AACS; 2002 AACS; 2013 AACS; 2016 AACS.  
R 338.3113a Schedule 1; depressants.  
Rule 13a. Unless specifically excepted or unless listed in another schedule, any  
material, compound, mixture, or preparation which contains any quantity of the  
following substances having a depressant effect on the central nervous system,  
including its salts, isomers, and salts of isomers when the existence of such salts,  
isomers, and salts of isomers is possible within the specific chemical designation is  
included in schedule 1:  
(a) Gamma-hydroxbutyric acid.  
Some other names:  
(i) GHB.  
(ii) gamma-hydroxybutyrate.  
(iii) 4-hydroxybutyrate.  
(iv) 4-hydroxybutanoic acid.  
(v) sodium oxybate.  
(vi) sodium oxybutyrate.  
(b) Mecloqualone.  
(c) Methaqualone.  
History: 1988 AACS; 2002 AACS.  
R 338.3114 Schedule 1; tetrahydrocannabinols.  
Rule 14. Synthetic equivalents of the substances contained in the plant or in the  
resinous extractives of cannabis and synthetic substances, derivatives, and their isomers  
with similar chemical structure or pharmacological activity, or both, such as the  
following, are included in schedule 1:  
Substance  
a
Δ1 cis or trans tetrahydrocannabinol and their optical isomers, excluding  
dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug  
product approved by the United States food and drug administration.  
b
c
Δ6 cis or trans tetrahydrocannabinol and their optical isomers.  
Δ3,4 cis or trans tetrahydrocannabinol and their optical isomers. Since the  
Page 9  
nomenclature of these substances is not internationally standardized, compounds  
of these structures, regardless of numerical designation of atomic positions, are  
included.  
d
Synthetic cannabinoids. As used in this subrule, “synthetic cannabinoids” includes  
any material, compound, mixture, or preparation that is not otherwise listed as a  
controlled substance in this schedule or in schedules II through V, is not approved  
by the federal food and drug administration as a drug, and contains any quantity of  
the following substances, their salts, isomers (whether optical, positional, or  
geometric), homologues (analogs), and salts of isomers and homologues (analogs),  
unless specifically excepted, whenever the existence of these salts, isomers,  
homologues (analogs), and salts of isomers and homologues (analogs) is possible  
within the specific chemical designation:  
i
Any compound containing a 3-(1-naphthoyl)indole structure, also known as  
napthoylindoles, with substitution at the nitrogen atom of the indole ring by an  
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further  
substituted on the indole ring to any extent and whether or not substituted on the  
naphthyl ring to any extent. Examples of this structural class include but are not  
limited to: JWH-007, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-  
122, JWH-200, JWH-210, JWH-398, AM-1220, AM-2201, and WIN-55, 212-2.  
Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure, also  
known as napthylmethylindoles, with substitution at the nitrogen atom of the  
indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-  
(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not  
further substituted on the indole ring to any extent and whether or not substituted  
on the naphthyl ring to any extent. Examples of this structural class include but are  
not limited to: JWH-175, JWH-184.  
ii  
iii  
Any compound containing a 3-(1-naphthoyl)pyrrole structure, also known as  
naphthoylpyrroles with substitution at the nitrogen atom of the pyrrole ring by an  
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further  
substituted on the pyrrole ring to any extent and whether or not substituted on the  
naphthyl ring to any extent. Examples of this structural class include but are not  
limited to: JWH-370, JWH-030.  
iv  
v
Any compound containing a naphthylideneindene structure with substitution at the  
3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl) ethyl  
group, whether or not further substituted on the indene ring to any extent and  
whether or not substituted on the naphthyl ring to any extent. An example of this  
structural class includes, but is not limited to, JWH-176.  
Any compound containing a 3-phenylacetylindole structure, also known as  
phenacetylindoles, with substitution at the nitrogen atom of the indole ring by an  
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further  
substituted on the indole ring to any extent and whether or not substituted on the  
phenyl ring to any extent. Examples of this structural class include but are not  
Page 10  
limited to: RCS-8 (SR-18), JWH-250, JWH-203, JWH-251, and JWH-302.  
Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure, also known  
as cyclohexylphenols, with substitution at the 5-position of the phenolic ring by an  
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted on  
the cyclohexyl ring to any extent. Examples of this structural class include but are  
not limited to: CP-47,497 (and homologues (analogs)), cannabicyclohexanol, and  
CP-55,940.  
vi  
vii  
Any compound containing a 3-(benzoyl)indole structure, also known as  
benzoylindoles, with substitution at the nitrogen atom of the indole ring by an  
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further  
substituted on the indole ring to any extent and whether or not substituted on the  
phenyl ring to any extent. Examples of this structural class include but are not  
limited to: AM-694, pravadoline (WIN-48,098), RCS-4, AM-630, AM-679, AM-  
1241, and AM-2233.  
viii  
ix  
Any compound containing a 11-hydroxy-Δ8-tetrahydrocannabinol structure, also  
known as dibenzopyrans, with further substitution on the 3-pentyl group by an  
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkyethyl, 1-(N-methyl-2-  
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group. Examples of this structural  
class include but are not limited to: HU-210, JWH-051, JWH-133.  
Any compound containing a 3-(L-adamantoyl)indole structure, also known as  
adamantoylindoles, with substitution at the nitrogen atom of the indole ring by an  
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further  
substituted on the adamantyl ring system to any extent. An example of this  
structural class includes, but is not limited to, AM-1248.  
x
Any other synthetic chemical compound that is a cannabinoid receptor agonist and  
mimics the pharmacological effect of naturally occurring cannabinoids that is not  
listed in schedules II through V and is not approved by the federal food and drug  
administration as a drug.  
History: 1979 AC; 1986 AACS; 2013 AACS.  
R 338.3114a Schedule 1; stimulants.  
Rule 14a. Unless specifically excepted or unless listed in another schedule, any  
material, compound, mixture, or preparation which contains any quantity of the following  
substances having a stimulant effect on the central nervous system, including its salts,  
isomers, and salts of isomers, is included in schedule 1:  
Substance  
Trade or Other Names  
a
Aminorex  
aminoxaphen  
2-amino-5-phenyl-2-oxazoline  
4,5-dihydro-5-phenyl-2-oxazolamine  
2-amino-1-phenyl-1-propanone  
b
Cathinone  
Page 11  
alpha-aminopropiophenone  
2-aminopropiophenone  
norephedrone  
4-MMC  
4-methylmethcathinone  
m-CAT  
2-methyiamino-l-phenylpropan-1-one  
CAT  
Ephedrone  
3,4-Methylenedioxypyrovalerone  
MDPV  
c
d
e
Mephedrone  
Methcathinone  
Methylenedioxypyrovalerone  
Methadrone  
f
Fenethylline  
g
( )cis-4-methylaminorex([( )cis-  
4,5-dihydro-4-methyl-5phenyl-2-  
oxazolamine)  
h
i
N-ethylamphetamine  
N,N-dimethylamphetamine  
N,N-alpha-trimethyl-  
benzeneethanimine  
N,N-alpha-trimethylphenethylamine  
j
Synthetic cathinones. As used in this subrule, “synthetic cathinones” includes any  
material, compound, mixture, or preparation that is not otherwise listed as a  
controlled substance in this schedule or in schedules II through V, is not approved  
by the federal food and drug administration as a drug, and contains any quantity of  
the following substances, their salts, isomers (whether optical, positional, or  
geometric), homologues (analogs), and salts of isomers and homologues (analogs),  
unless specifically excepted, whenever the existence of these salts, isomers,  
homologues (analogs), and salts of isomers and homologues (analogs) is possible  
within the specific chemical designation:  
i
Any compound containing a 2-amino-1-propanone structure with substitution at the  
1-position with a monocyclic or fused polycyclic ring system and a substitution at  
the nitrogen atom by an alkyl group, cycloalkyl group, or incorporation into a  
heterocyclic structure. Examples of this structural class include, but are not limited  
to, dimethylcathinone, ethcathinone, and alpha-pyrrolidinopropiophenone.  
Any compound containing a 2-amino-1-propanone structure with substitution at the  
1-position with a monocyclic or fused polycyclic ring system and a substitution at  
the 3-position carbon with an alkyl, haloalkyl, or alkoxy group. An example of this  
structural class includes, but is not limited to, naphyrone.  
ii  
iii  
Any compound containing a 2-amino-1-propanone structure with substitution at the  
1-position with a monocyclic or fused polycyclic ring system and a substitution at  
any position of the ring system with an alkyl, haloalkyl, halogen, alkylenedioxy, or  
alkoxy group, whether or not further substituted at any position on the ring system  
to any extent. Examples of this structural class include, but are not limited to,  
mephedrone, methylone, and 3-fluoromethylone.  
Page 12  
History: 1988 AACS; 1994 AACS; 2002 AACS; 2013 AACS.  
R 338.3116 Schedule 2; substances of vegetable origin or chemical synthesis.  
Rule 16. (1) Unless specifically excepted, the following substances of vegetable origin,  
or independently derived by means of chemical synthesis or by combination of extraction  
and chemical synthesis, are included in schedule 2:  
(a) Opium and opiate, and any salt, compound, derivative, or preparation of opium or  
opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and  
naltrexone, and their respective salts, but including all of the following:  
Substance  
i
Raw opium  
ii  
iii  
iv  
v
Opium extracts  
Opium fluid extracts  
Powdered opium  
Granulated opium  
Tincture of opium  
Codeine  
Ethylmorphine  
Etorphine hydrochloride  
Hydrocodone  
Hydromorphone  
Metopon  
Morphine  
Oripavine  
Oxycodone  
Oxymorphone  
Thebaine  
vi  
vii  
viii  
ix  
x
xi  
xii  
xiii  
xiv  
xv  
xvi  
xvii  
(b) A salt, compound, derivative, or preparation thereof which is chemically  
equivalent to or identical with a substance referred to in subdivision (a) of this subrule,  
except that these substances do not include the isoquinoline alkaloids of opium.  
(c) Opium poppy, poppy straw, and concentrate of poppy straw (the crude extract of  
poppy straw in either liquid, solid, or powder form, which contains the phenathrine  
alkaloids of the opium poppy).  
(d) Coca leaves, and any salt, compound, derivative, or preparation of coca leaves,  
and any salt, compound, derivative, or preparation which is chemically equivalent to or  
identical with any of these substances.  
(e) Cocaine; its salts; isomers; whether optical, position, or geometric; and salts of  
isomers.  
(2) Decocainized coca leaves or the extraction of coca leaves, which extractions do  
not contain cocaine or ecgonine, are specifically excepted from schedule 2.  
History: 1979 AC; 1986 AACS; 1994 AACS; 2013 AACS.  
Page 13  
R 338.3117 Schedule 2; opiates.  
Rule 17. Unless specifically excepted, the following opiates, including their isomers,  
esters, and ethers, when the existence of these isomers, esters, ethers, and salts is possible  
within the specific chemical designation, are included in schedule 2:  
Substance  
Trade or Other Names  
a
b
c
d
e
f
Alfentanil  
Alphaprodine  
Anileridine  
Benzitramide  
Bulk propoxyphene (nondosage forms)  
Carfentanil  
g
h
i
Dihydrocodeine  
Dihydroetorphine  
Diphenoxylate  
j
Fentanyl  
k
l
Isomethadone  
Levo-alphacetylmethadol  
Levo-alpha-acetylmethadol  
Levomethadyl Acetate  
LAAM  
m
n
Levomethorphan  
Levorphanol  
o
Metazocine  
p
Methadone  
q
Methadone-Intermediate, 4 cyano-2-  
dimethylamino-4,4 diphenyl butane  
Moramide-Intermediate, 2-methyl-3-  
r
morpholino-1,  
carboxylic acid  
1-diphenyl-propane-  
s
t
Pethidine (meperidine).  
Pethidine-Intermediate-A, 4-cyano-1-1  
methyl-4-phenylpiperidine  
u
v
Pethidine-Intermediate-B,  
phenylpiperidine-4-carboxylate  
Pethidine-Intermediate-C, 1-methyl-4-  
phenylpiperidine-4-carboxylic acid  
Phenazocine  
ethyl-4-  
w
x
Piminodine  
y
z
Racemethorphan  
Racemorphan  
aa  
bb  
cc  
Remifentanil  
Sufentanil  
Tapentadol  
History: 1979 AC; 1985 AACS; 1988 AACS; 1995 AACS; 2002 AACS; 2013 AACS.  
Page 14  
R 338.3118 Schedule 2; stimulants.  
Rule 18. Unless specifically excepted or unless listed in another schedule, any material,  
compound, mixture, or preparation which contains any quantity of the following  
substances and which has a stimulant effect on the central nervous system is included in  
schedule 2:  
Substance  
a
b
c
d
e
Amphetamine, its salts, optical isomers and salts of its optical isomers  
Lisdexamfetamine, its salts, optical isomers and salts of its optical isomers  
Methamphetamine, its salts, isomers and salts of its isomers  
Phenmetrazine and its salts  
Methylphenidate and its salts  
History: 1979 AC; 1992 AACS; 2013 AACS.  
R 338.3119 Schedule 2; depressants.  
Rule 19. Unless specifically excepted or unless listed in another schedule, any  
material, compound, mixture, or preparation which contains any quantity of the  
following substances having a depressant effect on the central nervous system,  
including its salts, isomers, and salts of isomers, when the existence of such salts,  
isomers, and salts of isomers is possible within the specific chemical designation, is  
included in schedule 2:  
(a) Amobarbital.  
(b) Glutethimide.  
(c) Pentobarbital.  
(d) Phencyclidine.  
(e) Secobarbital.  
(f) Any compound, mixture, or preparation containing amobarbital, secobarbital,  
pentobarbital, or any salt thereof in combination with itself, one another, or 1 or  
more other controlled substances.  
History: 1979 AC; 1986 AACS; 1992 AACS.  
R 338.3119a Schedule 2; hallucinogenic substances.  
Rule 19a. Unless specifically excepted or unless listed in another schedule, any  
material, compound, mixture, or preparation which contains any quantity of nabilone,  
including its salts, isomers, and salts of isomers when the existence of these salts,  
isomers, and salts of isomers is possible within the specific chemical designation, is  
included in schedule 2.  
History: 1986 AACS; 1994 AACS; 2002 AACS.  
Page 15  
R 338.3119b Schedule 2; immediate precursors.  
Rule 19b. Unless specifically excepted or unless listed in another schedule, any  
material, compound, mixture, or preparation that contains  
any quantity of the following substances:  
(a) Immediate precursor to amphetamine and methamphetamine:  
Phenylacetone  
Some trade or other names:  
Phenyl-2-propanone;  
P2P;  
Benzyl methyl ketone;  
Methyl benzyl ketone.  
(b) Immediate precursors to phencyclidine (PCP):  
(i) 1-phenylcyclohexylamine.  
(ii) 1-Piperidinocyclohexanecarbonitrile (PCC).  
History: 1994 AACS.  
R 338.3120 Schedule 3; stimulants; depressants; nalorphine.  
Rule 20. (1) Unless specifically excepted or unless listed in another schedule, a  
material, compound, mixture, or preparation that contains any quantity of the following  
substances having a stimulant effect on the central nervous system, including its salts,  
isomers whether optical, position, or geometric, and the salts of such isomers, when the  
existence of such salts, isomers, and the salts of isomers is possible within the specific  
chemical designation, is included in schedule 3:  
(a) Benzphetamine.  
(b) Chlorphentermine.  
(c) Clortermine.  
(d) Phendimetrazine.  
(2) Unless specifically excepted or unless listed in another schedule, a material,  
compound, mixture, or preparation that contains any quantity of the following substances  
having a depressant effect on the central nervous system, including its salts, isomers  
whether optical, position, or geometric, and the salts of such isomers, when the existence  
of such salts, isomers, and the salts of isomers is possible within the specific chemical  
designation, is included in schedule 3:  
(a) Chlorhexadol.  
(b) Embutramide.  
(c) Any drug product containing gamma hydroxybutyric acid, including its salts,  
isomers, and salts of isomers, for which an application is approved under section 505 of  
the federal food, drug, and cosmetic act of 1938, 21 U.S.C.§301 et seq.  
(d) Ketamine.  
(e) Lysergic acid.  
(f) Lysergic acid amide.  
(g) Methyprylon.  
(h) Perampanel.  
(i) Pentazocine.  
(j) Sulfondiethylmethane.  
Page 16  
(k) Sulfonethylmethane.  
(l) Sulfonmethane.  
(m) Tiletamine-zolazepam.  
(3) A compound, mixture, or preparation containing amobarbital, secobarbital,  
pentobarbital, or a salt thereof and 1 or more other active medicinal ingredients that are  
not listed in a schedule is included in schedule 3.  
(4) A suppository dosage form which contains amobarbital, secobarbital,  
pentobarbital, or a salt of any of these drugs and which is approved by the food and drug  
administration for marketing only as a suppository is included in schedule 3.  
(5) A substance that contains any quantity of a derivative of barbituric acid or any salt  
thereof is included in schedule 3.  
(6) Nalorphine is included in schedule 3.  
(7) Buprenorphine is included in schedule 3.  
History: 1979 AC; 1982 AACS; 1988 AACS; 1992 AACS; 2002 AACS; 2007 AACS; 2016 AACS.  
R 338.3121 Schedule 3; narcotic drugs.  
Rule 21. Unless specifically excepted, any material, compound, mixture, or  
preparation containing limited quantities of any of the following narcotic drugs or any  
salts thereof is included in schedule 3:  
(a) Not more than 1.8 grams of codeine per 100 milliliters and not more than 90  
milligrams per dosage unit when combined with an equal or greater quantity of an  
isoquinoline alkaloid of opium.  
(b) Not more than 1.8 grams of codeine per 100 milliliters and not more than 90  
milligrams per dosage unit, with 1 or more active ingredients in recognized therapeutic  
amounts.  
(c) Not more than 1.8 grams of dihydrocodeine per 100 milliliters and not more than  
90 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in  
recognized therapeutic amounts.  
(d) Not more than 300 milligrams of ethylmorphine per 100 milliliters and not more  
than 15 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in  
recognized therapeutic amounts.  
(e) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams and  
not more than 25 milligrams per dosage unit, with 1 or more active, nonnarcotic  
ingredients in recognized therapeutic amounts.  
(f) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams and  
not more than 2.5 milligrams per dosage unit, with 1 or more active, nonnarcotic  
ingredients in recognized therapeutic amounts, including paregoric.  
History: 1979 AC; 2016 AACS.  
R 338.3121a Schedule 3; hallucinogenic substances.  
Rule 21a. Unless specifically excepted or unless listed in another schedule, any  
material, compound, mixture, or preparation which contains any quantity of dronabinol  
(synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United  
Page 17  
States food and drug administration approved drug product and that has a  
hallucinogenic effect on the nervous system, including its salts, isomers, and salts of  
isomers  
when  
the existence of these salts, isomers, and salts of isomers  
is  
possible within the specific chemical designation, is included in schedule 3.  
History: 2002 AACS.  
R 338.3122 Schedule 3; anabolic steroids; exemptions.  
Rule 22. (1) Unless specifically excepted or unless listed in another schedule, any  
material, compound, mixture, or preparation that contains any quantity of an anabolic  
steroid, including its salts, isomers, and salts of isomers if the existence of such salts of  
isomers is possible within the specific chemical designation, is included in schedule 3. As  
used in this rule, the term "anabolic steroid means any of the following drugs or  
hormonal substances which are chemically and pharmacologically related to testosterone,  
other than estrogens, progestins, and corticosteroids, and which promote muscle growth:  
Substance  
a
1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene; 3alpha,17beta-  
dihydroxy-5alphaandrost-1-ene)  
b
c
d
e
f
1-Androstenedione (5alpha-androst-1-en-3,17-dione)  
3Alpha,17beta-dihydroxy-5alpha-androstane  
3Beta,17beta-dihydroxy-5alpha-androstane  
4-Androstenediol (3beta,17beta-dihydroxy-androst-4-ene)  
4-Androstenedione (androst-4-en-3,17-dione)  
g
h
i
4-Hydroxy-19-nortestosterone (4,17beta-dihydroxyestr-4-en-3-one)  
4-Hydroxytestosterone (4,17beta-dihydroxyandrost-4-en-3-one)  
5-Androstenediol (3beta,17beta-dihydroxy-androst-5-ene)  
5-Androstenedione (androst-5-en-3,17-dione)  
j
k
l
m
n
o
13Beta-ethyl-17beta-hydroxygon-4-en-3-one  
17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane  
17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane  
17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene  
17Alpha-methyl-4-hydroxynandrolone  
hydroxyestr-4-en-3-one)  
(17alpha-methyl-hydroxy-17beta-  
p
17Alpha-methyl-delta1-dihydrotestosterone  
5alpha-androst-1-en-3-one)  
19-nor-4, 9(10)-androstadienedione.  
19-nor-5-androstendedione (estr-5-en-3, 17-dione)  
Boldenone  
(17beta-hydroxy-17alpha-methyl-  
q
r
s
t
Bolasterone  
u
v
w
x
y
Boldione  
Calusterone  
4-chlortestosterone (clostebol)  
Dehydrochlormethyltestosterone  
Desoxymethyltestosterone  
Page 18  
z
Drostanolone